Researchers have joined forces to design using artificial intelligence and produce next-generation viral particles to be applied in advanced therapies. These particles can be used in immunotherapies, ...
Spanish biotech OneChain Immunotherapeutics (OCI), has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA)to OC-1, a CAR T therapy against for the treatment of acute lymp...
OneChain Immunotherapeutics (OCI), a clinical stage biotech company focused on the development of CAR-T candidates for the treatment of oncological diseases, today announced the closing of a €6.7 mi...
The Josep Carreras Leukaemia Research Institute, a public centre pertaining to the Generalitat de Catalunya's (Government of Catalonia) CERCA network, has created the OneChain Immunotherapeutics (OCI)...